Welcome to our dedicated page for Entero Therapeutics SEC filings (Ticker: ENTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Entero Therapeutics, Inc. (NASDAQ: ENTO) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, including Forms 10-K, 10-Q, 8-K, registration statements, and other required reports. These documents provide detailed information on Entero’s dual focus: late clinical-stage development of targeted, non-systemic therapies for gastrointestinal diseases and the integration of Grid AI, a grid-edge, AI-driven software and device platform.
In its S-1/A registration statement, Entero outlines its GI pipeline and describes Adrulipase as a recombinant lipase enzyme for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. The same filing explains that the company is a smaller reporting company with common stock listed on the Nasdaq Capital Market under the symbol ENTO. Investors can use annual reports on Form 10-K and quarterly reports on Form 10-Q, when filed, to review research and development activities, risk factors, and financial statements.
Recent Forms 8-K are particularly important for understanding Entero’s corporate transition. One 8-K details the share exchange agreement through which Entero acquired 100% of Grid AI Corp, issuing common and Series H non-voting convertible preferred stock and granting Grid AI shareholders the right, subject to conditions, to designate a majority of directors. Other 8-K filings describe Nasdaq correspondence regarding compliance with Listing Rule 5550(b)(1), a Securities Purchase Agreement for a promissory note and warrant financing, and governance arrangements related to Grid AI’s shareholders and board representation.
A Form 12b-25 (NT 10-Q) explains that Entero requested additional time to file a quarterly report due to the complexity of accounting for the Grid AI acquisition. Together, these filings allow investors to track equity structure, financing arrangements, listing compliance, and the accounting treatment of major transactions. On Stock Titan, AI-powered tools summarize lengthy documents such as 10-Ks, 10-Qs, and 8-Ks, highlight key terms in registration statements like the S-1/A, and help surface notable items in ownership and governance disclosures, so readers can more quickly interpret ENTO’s regulatory history and ongoing obligations.
Document scope and corporate actions: This S-1/A incorporates the company’s 2024 Annual Report on Form 10-K and 10-Qs for March 31, 2025 and June 30, 2025 and states that all historical share and per-share figures reflect a 1-for-3 reverse stock split effective August 18, 2025. The filing lists authorized capital of 100,000,000 common shares and 10,000,000 preferred shares.
Intellectual property and patents: The filing references multiple patent families, including European and U.S. patents for a Yarrowia lipolytica lipase (European expiry June 15, 2026; U.S. expirations Sept 11, 2028 and July 17, 2026) and issued U.S. patents for inflammatory-condition treatments expiring Sept 1, 2036 and patents directed to niclosamide use expiring March 31, 2040.
Other material items: The prospectus lists risks and cost items related to development, regulatory approval, manufacturing, commercialization, patent prosecution and personnel. It discloses selling-stockholder warrant holdings with a 4.9% beneficial ownership exercise limitation and includes signatures dated September 10, 2025.